van Wyk J, Orkin C, Rubio R, Bogner J, et al. Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and -2 Randomized Clinical Trials. J Acquir Immune Defic Syndr 2020 Jul 13. doi: 10.1097/QAI.0000000000002449.
PMID: 32675772